2 news items
Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
COCP
13 May 24
is responsible
Cocrystal Pharma Receives Pre-IND Responses From The FDA On Oral CC-42344 For Treating Influenza A
COCP
19 Mar 24
before filing the trial design. The feedback was provided in a written response to a Pre-IND package and questions submitted by the Company in January
- Prev
- 1
- Next